|
| |
resverlogix clinical contacts Pages on BioPortfolio:
Results from other life science and pharmaceutical sites:
Resverlogix Corporation Reverse Cholesterol Transport by RVX-208 a ...
6 Nov 2007 ... CONTACT: please contact: Theresa Kennedy, VP, Corporate Communications, Resverlogix Corp., Phone: (604) 538-7072, Fax: (403) 256-8495, ...
http://www.biospace.com/news_story.aspx?NewsEntityId=76383...
|
BioWorld Online
Donald J. McCaffrey, President and CEO of Resverlogix stated, "We are very pleased to be able to share this exciting clinical information with the Clinical
...
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=BIOWORLD.s...
|
Jan Gray Joins Resverlogix Corporation Board of Di - News ...
... done a wonderful job moving forward its lead drug into clinical trials. ... CONTACT: Theresa Kennedy, VP, Corporate Communications, Resverlogix Corp., ...
http://www.biospace.com/news_story.aspx?NewsEntityId=104810...
|
BioPortfolio - Resverlogix Corporation - Profile
Contact Details:. 202, 279 Midpark Way SE. Calgary. Alberta ... Resverlogix advances to second arm of Phase 1b/2a clinical trial ...
http://www.bioportfolio.com/biocorporate/29213-Resverlogix+C...
|
Resverlogix Corporation Advances to Second Arm of Phase 1b/2a ...
Due to the nature of double blinded clinical trials and strict embargo rules ... CONTACT: Theresa Kennedy, VP, Corporate Communications, Resverlogix Corp., ...
http://www.biospace.com/news_story.aspx?NewsEntityId=113808...
|
Pharmahorizons Life Science | Pharmahorizons is a internet ...
Resverlogix's novel drug demonstrated the ability to increase the ... studies and our Phase 1a human clinical trial at the AHA," stated Dr. Jan Johansson, ...
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=pharmabio....
|
BioSpace - Print News Article
CONTACT: Theresa Kennedy, VP, Corporate Communications, Resverlogix Corp., Phone : (604) 538-7072, Fax: (403) 256-8495, Email: Theresa@resverlogix.com; ...
http://www.biospace.com/news_print.aspx?NewsEntityId=116674...
|
News: Resverlogix Initiates Alzheimer's Research Program. Genetic ...
"There remains a great unmet need in this therapeutic area," stated Jan Johansson, senior vp of clinical affairs at Resverlogix. ...
http://www.genengnews.com/news/bnitem.aspx?name=13778022...
|
BioPortfolio - Scientific Sessions - Profile
Contact Details:. 108 Wilmot Road, Suite 400. Deerfield. Illinois. 60015-0825 ... Resverlogix advances to second arm of Phase 1b/2a clinical trial ...
http://www.bioportfolio.com/biocorporate/29708-Scientific+Se...
|
News: RVX-208 Exploratory Study Illustrates Early Potential for ...
Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit ... Accelerating Research into Clinical Setting ...
http://www.genengnews.com/news/bnitem.aspx?name=45212082&chi...
|
|
